Five products of Tylenol $11.4 billion, 72%↑… Geworin $6.6 billion 84.7%↑
EZN6any 40%, GNAL-N 24.7%, ADVIL 104.7%, Champ 99.6%, Pan Cold-S 56.9% growth
In the first quarter, the sales of major pain reliever • fever reducer • anti-inflammatory that can be purchased without a doctor’s prescription have increased as fewer people visit a hospital due to COVID-19.
As many cases of late diagnosis due to the use of fever reducer have been controversial, more accurate analysis of the background of such changes in the market is needed.
The drugs are used to relieve early cold symptoms, such as pain and fever, as well as chills, but these symptoms are similar to the main COVID-19 symptoms, which make it difficult to diagnose the initial stage of patients who can spread the virus easily.
According to the Newsmp IQVIA data of major pain reliever • fever reducer • anti-inflammatory’s sales in the first quarter, most of them grew more than 50% than the same period of last year.
In particular, Tylenol (Johnson & Johnson • Janssen), which was considered as a drug to be used carefully when there are suspected symptoms of COVID-19 due to liver damage, exceeded $10 billion in sales in the first quarter, from $6.6 billion to $11.4 billion.
Among the types of Tylenol, sales of Tylenol accelerated from $3.9 billion to $6.5 billion, Tylenol 8 hours ER Tab. from $2 billion to $3.6 billion, and Tylenol cold-S Tab. from $0.5 billion to $1.1 billion, making 7.19% increase compared to the same period of last year.
Geworin (Samjin Pharm.) also soared its quarterly sales 84.7%, from $3.6 billion to $6.6 billion in the same period while EZN 6 Eve & Pro (Daewoong Pharm) made to $0.6 billion, and its combined sales have increased 41.4% from $1.4 billion to $2 billion.
Champ (Dong-A Pharm.), which has been specialized as a fever reducer for children, has doubled its sales to $1.2 billion, which was $0.6 billion in the same period last year.
Although smaller than these, sales of ADVIL (Pfizer) doubled from $0.3 billion to $0.6 billion, and GNAL-N (KyungDong Pharm.) also grew its major products evenly, resulting in 25% growth from $0.3 billion to $0.4 billion.
Moreover, Pan Cold-S (Dong Wha Pharm.)’s sales rose 56.8% from $5.2 billion to $8.1 billion, making $8 billion at a stroke, that led to parallel with PanPyrin (Dong-A Pharm.) which went round in circles.
Meanwhile, PanPyrin, which had low growth compared to other products, grew 4.3% in sales from $7.9 billion to $8.3, and Penzal (Chong Kun Dang) maintained a $1.3 billion range.
